Exactech Inc. EXAC recently unveiled a new Acapella One Cervical Spacer System at the North American Spine Society (NASS) Annual Meeting being held in Chicago, IL.
Acapella One is a cervical cage possessing integrated anchors designed to assist surgeons during anterior cervical spine fusions. Moreover, the single step deployment of the two integrated anchors makes the overall procedure of spine surgeries much simpler.
The device was created by Exactech with the help of specialists in the field. The overall objective is to minimize the time taken to complete an entire spinal operation procedure. Also, the device comes in various sizes to suit varied patient needs.
Exactech provides orthopedic implant devices to different users. Acapella One is yet another achievement for Exactech in the spine care space close on the heels of the recent launch of the Ambassador Anterior Cervical Plate System.
Meanwhile, Exactech introduced ExactechGPS Guided Personalized Surgery following the acquisition of BlueOrtho SAS. This system is designed to provide real-time visual guidance and alignment data in total joint arthroplasty to orthopedic surgeons.
In June, Exactech received FDA approval to market its Optetrak Logic Constrained Condylar (CC) Prosthesis. The system was approved for revision knee arthroplasty cases.
Notably, Exactech has a clinically recognized knee system that offers advanced approaches to knee replacement. The FDA clearance of Optetrak Logic CC further expands the Exactech Knee system offerings for surgeons who desire predictable and reproducible outcomes.
We believe that the rollout of new and innovative products will help the company gain market traction, which in turn, will help drive revenues going forward.
However, currency fluctuations will continue to hurt overall results over the next couple of quarters. Moreover, pricing pressure remains a serious concern in the near term.
Zacks Rank & Key Picks
Exactech currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the industry include Cyberonics Inc. CYBX, Masimo Corporation MASI and Cesca Therapeutics KOOL. Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment